Bill Novotny, M.D.
Senior Vice President, Clinical Development
Bill Novotny, M.D., is Senior Vice President of Clinical Development at Prelude Therapeutics. He is a physician-scientist with a 30-year career spanning academic and basic science, hematology-oncology drug development, oncology diagnostics and clinical practice of medicine. Bill led the development of Avastin, the first angiogenesis-inhibitor for the treatment of colon, lung and breast cancer, from Phase 1 to FDA approval. Other first-in-class drugs that Bill helped develop and bring to market include Herceptin for the treatment of breast cancer, and enzalutamide for the treatment of prostate cancer. Prior to joining Prelude, Dr. Novotny was Senior Vice President of Hematology at BeiGene, where he oversaw development, and approval of zanubrutinib in B cell malignancies and tislelizumab in Hodgkin lymphoma. He has held senior positions at GRAIL, Medivation and Genomic Health. He began his career in biotech at Genentech, where as Principal Medical Director from 1995 to 2009, he led the development of Avastin, sibrafiban, and Apo2L/TRAIL, and contributed to the early development and approval of Herceptin.